People · Operator
Named in public records as an officer, director or promoter · active 2009–2025 · Pharma, Biotechnology, Other
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Cognito Therapeutics Group, Inc. | — | Pharma | Series D+ | $196.3M | $1.7B | 2025 |
| Cognito Therapeutics Ltd. | — | Pharma | Series D+ | $119.0M | $111.6M | 2022 |
| Elucid Bioimaging Inc. | — | Biotechnology | Series C | $115.8M | $200.2M | 2025 |
| Epitek, Inc | — | Other | Pre-Seed | $750K | $17.3M | 2009 |
Richard Kuntz at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Richard Kuntz on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Gerald Chan | 2 | 13 |
| Stephen Bruso | 2 | 9 |
| Helen Liang | 2 | 4 |
| Laura Brege | 2 | 3 |
| Scott Huennekens | 1 | 7 |
| Evan Melrose | 1 | 4 |
| Travis Murphy | 1 | 3 |
| Scott Halsted | 1 | 3 |
| Jarod Rutledge | 1 | 2 |
| Blake Richards | 1 | 2 |
| Jean-Paul Rasschaert | 1 | 2 |
| Andrew J. Buckler | 1 | 1 |
| Christian Howell | 1 | 1 |
| Brent Vaughan | 1 | 1 |
| Jeffrey Halis | 1 | 1 |
| Stephen Ghiglieri | 1 | 1 |
| Zach Malchano | 1 | 1 |
| Todd Stolpman | 1 | 1 |
| Christopher Joyce | 1 | 1 |
| Stan Myrum | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.